肺结核病合并胸膜炎应用巩固化疗方案的疗效分析

目的研究肺结核病合并胸膜炎患者应用巩固化疗方案的临床疗效。方法选取2010年6月-2012年6月金堂县第二人民医院收治的200例肺结核病合并胸膜炎患者,首先选用利福平、乙胺丁醇、异烟肼及吡嗪酰胺药物进行强化期治疗2个月,而后将这些患者平均分成两组,观察组(A组)每周1次利福喷丁,外加每周2次异烟肼;对照组(B组)每天应用1次利福平、异烟肼,以6个月为1个疗程。结果在治疗结束后,两组患者在痰培养、结核病灶及胸水吸收等比较差异无统计学意义。在肝功能损害上,观察组低于对照组。结论对肺结核病合并胸膜炎患者实施每周1次的巩固治疗,能够取得显著疗效,提高患者的耐受性,减轻毒副作用。

Objective To study TB pleurisy patients merger consolidation chemotherapy clinical efficacy. Methods In the hospital from June 2010 to June 2012 were treated 200 cases of TB pleurisy patients combined, the first choice of rifampicin, ethambutol, isoniazid and pyrazinamide in the intensive phase of treatment of two drugs months, and after these patients were divided into two groups, the observation group （A group） once weekly rifapentine plus isoniazid twice a week;the control group （B） applied once daily rifampin, isoniazid hydrazine to six months for a course of treatment. Results After treatment, the two groups of patients in the sputum, pleural fluid absorption tuberculosis and no difference was not statistically significant. In liver dysfunction, the observation group than the control group. Conclusion Patients with TB pleurisy implemented merger consolidation therapy once a week, it is possible to obtain a significant effect, improve the patient＇s tolerance, reduce side effects.